Experimental Targeted Immunotherapy Drug Performs Better Than Chemotherapy for Treatment of Advanced Lung Cancer

03/15/2016 | Kaiser Permanente
In global clinical trials, patients with advanced metastatic lung cancer who were treated with targeted immunotherapy drug atezolizumab lived significantly longer and with fewer side effects than those who received standard second-line chemotherapy, according to a new Kaiser Permanente study published March 15 in the medical journal The Lancet.

Not currently approved by the Food and Drug Administration, atezolizumab is one of a new class of genetically engineered antibodies that reduce the cancer’s ability to evade the natural immune reaction to many lung cancers.